期刊文献+

冠心病患者血清骨保护素和高敏C反应蛋白水平变化及其临床意义 被引量:2

Changes and clinical significance of serum osteoprotegerin and high sensitive C-reactive protein in patients with coronary heart disease
原文传递
导出
摘要 目的探讨冠心病患者血清骨保护素(OPG)和高敏C反应蛋白(hsCRP)水平变化及其临床意义。方法冠心病患者45例分为急性心肌梗死(AMI组,15例)、不稳定型心绞痛(UAP组,15例)和稳定型心绞痛(SAP组,15例);其中,主要冠状动脉狭窄≥50%为单支者23例、双支者12例、三支者10例。检测治疗前和治疗后1、2和4周血清OPG及hsCRP。健康人15例作为对照组。结果治疗前,冠心病患者的血清OPG和hsCRP水平均高于对照组(P<0.01)。治疗后1、2和4周,冠心病患者的血清OPG和hsCRP水平均降低(P<0.01),但仍然高于对照组(P<0.05或P<0.01)。冠心病患者血清OPG和hsCRP水平随着病情严重程度加重而升高(P<0.05)。结论血清OPG和hsCRP可作为评估冠心病患者病情严重程度的预测因素。 Objective To investigate the changes and clinical significance of serum osteoprotegerin(OPG)and high sensitive C-reactive protein(hsCRP)in the patients with coronary heart disease(CHD).Methods Serum levels of OPG and hsCRP were detected in CHD patients with acute myocardiac infarction(group AMI,15 cases),unstable angina pectoris(group UAP,15 cases)and stable angina pectoris(group SAP,15 cases)before and in the 1 st,2 nd and 4 th week after treatment,of whom 23 cases had one coronary artery lesion(stenosis≥50% ),12 cases had two artery lesions and 10 cases had three artery lesions.Fifteen healthy people were taken as the controls.Results Serum levels of OPG and hsCRP before treatment were significantly higher in CHD patients than those in healthy people(P〈0.01),which in the 1 st,2 nd and 4 th week after treatment were decreased(P〈0.01),but still higher than those in the controls(P〈0.05 or P〈0.01).Serum levels of OPG and hsCRP were increased as the illness state of CHD became severe(P〈0.05).Conclusion Serum levels of OPG and hsCRP can be used as the factors in predicting the severity of the illness state in the patients with CHD.
出处 《江苏医药》 CAS 2017年第22期1624-1626,共3页 Jiangsu Medical Journal
关键词 冠心病 骨保护素 高敏C反应蛋白 Coronary heart disease Osteoprotegerin High sensitive C-reactive protein
  • 相关文献

参考文献4

二级参考文献56

  • 1LIBBY P. Molecular bases of the acute coronary syndromes[J]. Circulation,1995,91:2844-2850.
  • 2YASUDA H, SHIMA N, NAKAGAWA N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL[J]. PNAS, 1998,95 : 3597-3602.
  • 3KIECHL S, SCHETT G, WENNING G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease[J]. Circulation, 2004,109 : 2175-2180.
  • 4JONO S, SHIOI A, IKARI Y, et al. Vascular calcifi cation in chronic kidney disease (Rev)[J]. J Bone Miner Metab, 2006,24 :176 -181.
  • 5SHUICHI J, YUJI I, ATSUSHI S, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease[J]. Circulation, 2002,9 : 1192-1194.
  • 6CRISAFULLI A, MICARI A, ALTAVILLA D, et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction[J]. Clin Science,2005,109:389-395.
  • 7SCHOPPET M, SCHAEFER J R, HOFBAUER L C, et al. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men[J]. Circulation, 2003,107 : e76-76.
  • 8LIBBY P. Inflammation in atherosclerosis[J]. Nature,2002,420:868-87.
  • 9HANSSON G K, LIBBY P, SCHONBECK U, et aI. Innate and adaptive immunity in the pathogenesis of atheroselerosis[J]. Circ Res, 2002,91 : 281 -291.
  • 10HOFBAUER L, CANDSCHOPPET M. Clinical implications of the osteoprotegerin/RANKI./RANK system for bone and vascular diseases [J]. JAMA, 2004,292,490-449.

共引文献21

同被引文献28

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部